Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Neuroscience
AstronauTx raises $61 million in series A funding
by Laurel Oldach
October 14, 2023
| A version of this story appeared in
Volume 101, Issue 34
AstronauTx, a London-based biotechnology company that aims to develop small-molecule drugs for neurodegenerative diseases, has closed a $61 million series A financing round led by the Novartis Venture Fund. AstronauTx focuses on restoring the function of brain cells called astrocytes. These are more numerous than neurons and play important roles in brain immunity and inflammation. The company is planning a clinical trial of its lead drug candidate, which it has not disclosed, in people with Alzheimer’s disease.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter